InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,989.86
(
1.12%
)
Post# of 252427
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119954
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 189575

Monday, 08/10/2015 9:17:04 AM

Monday, August 10, 2015 9:17:04 AM

Post# of 252427
BMY now owns 9.9% of QURE, pursuant to the previously announced collaboration between the companies:

http://www.uniqure.com/news/263/182/uniQure-Announces-Receipt-of-53-Million-from-Bristol-Myers-Squibb-for-Target-Selection-Payment-and-Additional-Equity-Investment.html

Bristol-Myers Squibb also acquired an additional 1.3 million ordinary shares of uniQure priced at $29.67 per share, providing net proceeds to the Company of approximately $38 million. The purchase price represents an approximately 26% premium over uniQure’s closing price per ordinary share on August 7, 2015. After this second equity closing, Bristol-Myers Squibb owns 9.9% of uniQure’s outstanding ordinary shares.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up